Valuation: Alamar Biosciences, Inc.

Market Cap 1.95B 1.69B 1.58B 1.45B 2.73B 186B 2.77B 18.52B 7.27B 92.7B 7.31B 7.15B 309B P/E 2026 *
-20.6x
P/E 2027 * -42x
Enterprise Value 1.77B 1.53B 1.43B 1.31B 2.48B 168B 2.51B 16.78B 6.59B 84.02B 6.63B 6.48B 280B EV / Sales 2026 *
15.6x
EV / Sales 2027 * 11.1x
Free-Float
73.32%
Yield 2026 *
-
Yield 2027 * -
1 day-0.88%
1 week+12.09%
Current month+10.80%
1 month+9.51%
3 months+17.87%
1 week 24.85
Extreme 24.85
29.3
1 month 23.32
Extreme 23.32
29.43
Current year 18.84
Extreme 18.845
29.43
1 year 18.84
Extreme 18.845
29.43
3 years 18.84
Extreme 18.845
29.43
5 years 18.84
Extreme 18.845
29.43
10 years 18.84
Extreme 18.845
29.43
Manager TitleAgeSince
Chief Operating Officer 63 31/07/2018
Chief Tech/Sci/R&D Officer - 31/12/2020
Chief Executive Officer 62 30/06/2018
Director TitleAgeSince
Chairman 62 30/06/2018
Director/Board Member 64 30/04/2020
Date Insider Type Main position Quantity % Market Cap.
16/04/26 Conversion

Chief Executive Officer

8,786,851 318.3919%
Change 5-day change 1-year change 3-year change Capi.($)
-0.88%+12.09% - - 1.96B
+0.38%+0.56%+29.20%+5.72% 214B
+0.16%+1.94%+2.46%-21.50% 140B
-0.40%+5.88%-21.17%+20.82% 133B
+3.27%+7.17%-52.11%-2.80% 69.19B
+0.39%+2.76%+13.62%+12.28% 51.28B
-0.36%+5.11%-14.27%-20.67% 50.43B
+0.16%+1.90%+24.83%+11.91% 39.85B
-0.08%+5.10%+43.92%+37.88% 39.27B
-0.35%+7.04%-20.40%+24.54% 32.32B
Average +0.23%+5.05%+0.68%+7.58% 77.09B
Weighted average by Cap. +0.35%+3.43%+2.87%+4.05%

Financials

2026 *2027 *
Net sales 113M 98.25M 92M 84.16M 159M 10.79B 161M 1.08B 422M 5.39B 425M 416M 17.94B 162M 141M 132M 120M 227M 15.43B 230M 1.54B 604M 7.71B 608M 595M 25.66B
Net income -73.16M -63.49M -59.45M -54.38M -103M -6.97B -104M -695M -273M -3.48B -275M -269M -11.59B -56.76M -49.26M -46.13M -42.19M -79.66M -5.41B -80.7M -540M -212M -2.7B -213M -208M -8.99B
Net Debt -182M -158M -148M -136M -256M -17.37B -259M -1.73B -680M -8.68B -685M -670M -28.89B -153M -132M -124M -113M -214M -14.54B -217M -1.45B -570M -7.27B -573M -561M -24.19B
Logo Alamar Biosciences, Inc.
Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
Employees
222
Date Price Change Volume
06/08/26 US$28.10 -0.88% 246,414
05/08/26 US$28.35 +4.57% 201,180
04/08/26 US$27.11 +0.15% 272,615
03/08/26 US$27.07 +6.74% 183,693
31/07/26 US$25.36 +1.16% 154,363
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
28.10USD
Average target price
31.80USD
Spread / Average Target
+13.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMR Stock